全文获取类型
收费全文 | 281550篇 |
免费 | 24968篇 |
国内免费 | 8694篇 |
专业分类
耳鼻咽喉 | 2112篇 |
儿科学 | 10138篇 |
妇产科学 | 5284篇 |
基础医学 | 25492篇 |
口腔科学 | 3918篇 |
临床医学 | 29494篇 |
内科学 | 39174篇 |
皮肤病学 | 4371篇 |
神经病学 | 16910篇 |
特种医学 | 5982篇 |
外国民族医学 | 18篇 |
外科学 | 22107篇 |
综合类 | 50991篇 |
现状与发展 | 33篇 |
一般理论 | 28篇 |
预防医学 | 19760篇 |
眼科学 | 4021篇 |
药学 | 22674篇 |
418篇 | |
中国医学 | 46142篇 |
肿瘤学 | 6145篇 |
出版年
2024年 | 948篇 |
2023年 | 5343篇 |
2022年 | 8452篇 |
2021年 | 13577篇 |
2020年 | 12783篇 |
2019年 | 10454篇 |
2018年 | 9903篇 |
2017年 | 10711篇 |
2016年 | 10877篇 |
2015年 | 10111篇 |
2014年 | 21141篇 |
2013年 | 20295篇 |
2012年 | 18540篇 |
2011年 | 20643篇 |
2010年 | 16654篇 |
2009年 | 14490篇 |
2008年 | 13366篇 |
2007年 | 13801篇 |
2006年 | 11993篇 |
2005年 | 10058篇 |
2004年 | 8282篇 |
2003年 | 7222篇 |
2002年 | 5313篇 |
2001年 | 4793篇 |
2000年 | 4001篇 |
1999年 | 3501篇 |
1998年 | 2835篇 |
1997年 | 2599篇 |
1996年 | 2354篇 |
1995年 | 2220篇 |
1994年 | 1939篇 |
1993年 | 1612篇 |
1992年 | 1535篇 |
1991年 | 1248篇 |
1990年 | 1090篇 |
1989年 | 945篇 |
1988年 | 916篇 |
1987年 | 814篇 |
1986年 | 719篇 |
1985年 | 1070篇 |
1984年 | 944篇 |
1983年 | 652篇 |
1982年 | 774篇 |
1981年 | 729篇 |
1980年 | 657篇 |
1979年 | 552篇 |
1978年 | 430篇 |
1977年 | 380篇 |
1976年 | 298篇 |
1975年 | 160篇 |
排序方式: 共有10000条查询结果,搜索用时 343 毫秒
21.
22.
23.
24.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
25.
26.
27.
《Vaccine》2022,40(16):2370-2378
Porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (M. hyopneumoniae, Mhp) are two of the most common pathogens involved in the porcine respiratory disease complex (PRDC) resulting in significant economic losses worldwide. Vaccination is the most effective approach to disease prevention. Since PRRSV and Mhp co-infections are very common, an efficient dual vaccine against these pathogens is required for the global swine industry. Compared with traditional vaccines, multi-epitope vaccines have several advantages, they are comparatively easy to produce and construct, are chemically stable, and do not have an infectious potential. In this study, to develop a safe and effective vaccine, B cell and T cell epitopes of PRRSV-GP5, PRRSV-M, Mhp-P46, and Mhp-P65 protein had been screened to construct a recombinant epitope protein rEP-PM that has good hydrophilicity, strong antigenicity, and high surface accessibility, and each epitope is independent and complete. After immunization in mice, rEP-PM could induce the production of high levels of antibodies, and it had good immunoreactivity with anti-rEP-PM, anti-PRRSV, and anti-Mhp antibodies. The anti-rEP-PM antibody specifically recognizes proteins from PRRSV and Mhp. Moreover, rEP-PM induced a Th1-dominant cellular immune response in mice. Our results showed that the rEP-PM protein could be a potential candidate for the development of a safe and effective multi-epitope peptide combined vaccine to control PRRSV and Mhp infections. 相似文献
28.
多囊卵巢综合征(polycystic ovary syndrome,PCOS)是一种内分泌代谢紊乱综合征,临床表现高度异质性。肥胖是PCOS异质性临床表现之一,超过50%的PCOS患者超重或肥胖。肥胖型PCOS主要表现为高雄激素血症、中心型肥胖和糖脂代谢紊乱,非肥胖型PCOS主要表现为黄体生成激素(luteinizing hormone,LH)水平异常升高。尽管肥胖型和非肥胖型PCOS均存在内分泌代谢异常,然而肥胖可加重PCOS糖脂代谢紊乱;肥胖型PCOS还表现脂肪代谢的异常。综述肥胖型PCOS患者的临床特征、性激素水平、糖脂代谢特征,旨在为肥胖型和非肥胖型PCOS患者新的分型诊治提供参考。 相似文献
29.
目的:对中药保质期或有效期进行系统的调研,探讨中药饮片设定保质期或有效期的依据及其必要性,为提高中药饮片质量、保障临床用药安全提供技术支撑,为药品监管部门制定有关法规提供科学依据。方法:以国家知识基础设施数据库(CNKI)为数据来源,采用文献计量学研究方法,选用检索词为“中药材”并“有效期”“饮片”并“有效期”,“饮片”并“保质期”“中药材”并“保质期”“中药材”并“效期”和“饮片”并“效期”,利用CNKI平台工具以及Excel统计工具进行统计分析。结果:经数据库检索、筛选,获取中药材、饮片保质期或有效期或效期的相关有效文献共85篇,其中关于中药、饮片保质期的相关文献26篇,中药、饮片有效期或效期的相关文献59篇;在59篇关于中药有效期的文献中,74.58%的文献对于中药是否应该制定有效期、如何制定有效期等展开了讨论,25.42%的文献为中药有效期研究的实验性文献。结论:本文从中药材、饮片保质期与有效期的现状,质量评价指标,研究方法,饮片分类、保质期制定的必要性,及其存在的问题和建议等方面进行了梳理和归纳,为中药饮片保质期制定,提供了详实的文献依据。 相似文献
30.